About Matriks Biotek
Matriks Biotek is a Healthcare company based in Ankara (Turkey) founded in 2002 by Haluk Ataoglu. ELISA kits for monitoring biological drugs are developed and offered. Its chief executive, as recorded, is Haluk Ataoglu. Its Indian entity Biospec Private Limited reported revenue of ₹1.44 Cr. Matriks Biotek offers products and services including Shikari® ELISA Kits, CoronaHunter® Products, and Custom ELISA Kits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery.
Company details
Founded in 2002 in Ankara, Turkey, the company operates in the biotechnology sector, focusing on diagnostic tools. A range of ELISA kits is provided for tracking biological drugs, including SHIKARI kits and Coronahunter kits for COVID-19 detection. These enzyme immunoassays enable qualitative and quantitative analysis of antibodies against specific drugs and biologics, supporting clinical and research applications.
- Headquarters Ankara, Turkey
- Founders Haluk Ataoglu
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website matriksbiotek.com
- Social LinkedIn X
- Legal Name Biospec Private Limited
- Date of Incorporation 25 Jun, 2007
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹1.44 Cr
FY 2024 · +2360% YoY
- Indian entity net profit₹24.9 Lakh
FY 2024 · 17% margin
- Indian entity EBITDA₹34 Lakh
FY 2024 · 24% margin
- Latest Funding Round$55.11K (USD), Grant
Jan 2020
- InvestorsEuropean Union
& 1 more
Associated legal entities of Matriks Biotek
Matriks Biotek operates through Biospec Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Biospec Private Limited CIN U72900MH2007PTC171963 | Active | 25 Jun 2007 | Mumbai, Maharashtra | ₹1.4 Cr | 2 | View details |
Products & Services of Matriks Biotek
Matriks Biotek offers a comprehensive portfolio of products and services, including Shikari® ELISA Kits, CoronaHunter® Products, and Custom ELISA Kits.
Kits for accurate monitoring of biological drugs in personalized medicine.
ELISA kits for reliable detection of COVID-19 antibodies.
Tailored kits for testing biosimilar drugs effectively.
Funding Insights of Matriks Biotek
- Total Rounds 2
- Last Round Grant — $55,110
- First Round $55,392
(Aug 2019)
- Investors Count 2
All 2 funding rounds of Matriks Biotek with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $55,110 | Grant | – | – | |
| Aug 2019 | $55,392 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Matriks Biotek
Matriks Biotek has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Matriks Biotek
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Biospec Private Limited (Matriks Biotek)
Biospec Private Limited is the primary company behind Matriks Biotek. The board of Biospec Private Limited currently have 2 directors; the longest-serving is Vipul Kalyanji Chhatbar, appointed in 2007.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vipul Kalyanji Chhatbar DIN 00303376 | Director | 25 Jun 2007 | 19 yrs 4 mo | Biospec Private Limited |
| Nikita Vipul Chhatbar DIN 00303497 | Director | 25 Jun 2007 | 19 yrs 4 mo | Biospec Private Limited |
People of Matriks Biotek
1 people are tracked at Matriks Biotek (1 in leadership).
| Name | Role | Group |
|---|---|---|
Haluk Ataoglu | Founder & CEO | Leadership |
Complete people profiles for Matriks Biotek
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Matriks Biotek
Figures of Biospec Private Limited, the primary company behind Matriks Biotek, for FY 2024. Revenue was ₹1.44 Cr (+2360% year on year). Net profit was ₹24.9 Lakh (17% margin). EBITDA was ₹34 Lakh (24% margin). Revenue has grown at a compounded annual rate of +93% over three years and +73% over five years.
- ₹1.44 CrRevenue · FY 2024 · +2360% YoY
- ₹24.9 LakhNet profit · 17% margin
- ₹34 LakhEBITDA · 24% margin
- ₹1 LakhPaid-up capital
- +93%Revenue CAGR, 3 years
- +73%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Biospec Private Limited are on its company page.
Detailed financial statements for Matriks Biotek
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Matriks Biotek
3 dated milestones of Matriks Biotek across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Matriks Biotek is founded.
- Funding First funding round of $55K.
- Funding Latest funding round, Grant, of $55K.
Web traffic of Matriks Biotek
The website of Matriks Biotek (matriksbiotek.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▼ 52.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Matriks Biotek
Complete news archive for Matriks Biotek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Matriks Biotek
Matriks Biotek was founded in 2002 and raised its 1st funding round 17 years after it was founded.
Matriks Biotek is headquartered in Ankara, Turkey. It is registered at Ankara, Ankara, Turkey.
Haluk Ataoglu is the CEO of Matriks Biotek, as recorded in our data. They have also founded this company.
The primary company behind Matriks Biotek, Biospec Private Limited, reported revenue of ₹1.44 Cr for FY 2024, up 2360% year on year.
Founded in 2002 in Ankara, Turkey, the company operates in the biotechnology sector, focusing on diagnostic tools. A range of ELISA kits is provided for tracking biological drugs, including SHIKARI kits and Coronahunter kits for COVID-19 detection. These enzyme immunoassays enable qualitative and quantitative analysis of antibodies against specific drugs and biologics, supporting clinical and research applications.
Matriks Biotek offers Shikari® ELISA Kits, CoronaHunter® Products, and Custom ELISA Kits.
Matriks Biotek has 2 investors. Key investors include European Union, and EIC Fund.
Matriks Biotek operates through Biospec Private Limited.
The legal entities of Matriks Biotek currently have 2 directors, including Vipul Kalyanji Chhatbar, Nikita Vipul Chhatbar.